Vivo Capital’s Portfolio Company, Preventice was Bought by Boston Scientific for $1.2B

Boston Scientic Inc. BSX, -1.31% said Thursday it has agreed to acquire privately held PreventiceSolutions Inc. for an upfront payment of $925 million and up to $300 million in potential milestonepayments. The company has been an investor in Preventice since 2015 and currently owns a 22% state.Preventice, which provides mobile cardiac services, including ambulatory cardiac monitors, had sales of$158 million in 2020, up 30% from the year-earlier period. “Cardiovascular disease is the leading causeof mortality globally, accounting for nearly 17.9 million annual global deaths and highlighting the needfor early detection and management for individuals who may be at risk of a cardiac event,” BostonScientic said in a statement. The deal is expected to close by mid-2021 and to be immaterial toadjusted earnings in the rst year, to boost adjusted earnings by at least one cent in 2022 and to beincreasingly accretive after that. “This acquisition will provide Boston Scientic with a foothold in thehigh-growth ambulatory electrocardiography space, which strongly complements our recent entranceinto the implantable cardiac monitor market and will serve as an important component of our categoryleadership strategy in cardiac diagnostics and services — a nearly $2B market anticipated to growdouble digits annually,” said Scott Olson, Boston Scientic senior vice president and president, RhythmManagement, in a statement. Shares were up 0.9% premarket, but have fallen 17% in the last 12 months,while the S&P 500 SPX, -0.30% has gained 16%.